Processa Pharmaceuticals 提交 8-K,披露致股东信
Processa Pharmaceuticals, Inc. (0001533743) (Filer)
Processa Pharmaceuticals 于 11 月 5 日提交 Form 8-K,披露公司当天向股东发出一封信,并将其作为附件 99.1 提交。文件标明相关材料属于《交易法》Rule 14a-12 下的征求材料;公司普通股代码为 PCSA,在纳斯达克交易。
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 5, 2026
Processa Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware |
001-39531 |
45-1539785 |
|
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
601 21st Street, Suite 300
Vero Beach, FL 32960
(Address of principal executive offices, including zip code)
(772) 453-2899
(Registrant’s telephone number, including area code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☒ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
Trade Symbol(s) |
Name of each exchange on which registered |
||
|
Common Stock, $0.0001 par value per share |
PCSA |
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 8.01 |
Other Events. |
On November 5, 2026, Processa Pharmaceuticals, Inc. (the “Company”) issued a letter to the Company’s stockholders (the “Stockholder Letter”). A copy of the Stockholder Letter is attached as Exhibit 99.1 to this Current Report on Form 8-K.
| Item 9.01 |
Financial Statements and Exhibits. |
(d) Exhibits.
|
Exhibit Number |
Description |
|
|
Stockholder Letter, dated November 5, 2026. |
||
|
104 |
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Processa Pharmaceuticals, Inc. |
||
|
Date: November 5, 2026 |
By: |
/s/ Russell Skibsted |
|
Name: |
Russell Skibsted |
|
|
Title: |
Chief Financial Officer |
|
来源:SEC EDGAR · 本站存档